CMC Biologics has completed the first stage of expansion at its manufacturing facility in Copenhagen, Denmark with the addition of a single-use Bioreactor 3PACK facility, which consists of three 2,000L single-use production bioreactors and associated seed train for scale up. This allows for flexible production with scales from 2,000L to 6,000L in a single production suite. The bioreactors can be run singly, simultaneously, sequentially or in staggered fashion to meet production needs. The 3PACK line is currently ready for production runs.
 
“With this additional cGMP production capacity, we are continuing our long-term strategy to provide innovative solutions to our customers, from early-stage development to large-scale commercial production,” said Patricio Massera, general manager of the Copenhagen Site.
 
Three additional 2,000L single-use production bioreactors will be added in 2017 to complete the fit out of a Bioreactor 6PACK line, establishing identical Bioreactor 6PACK facilities in its U.S. and European manufacturing facilities.